RTW Investments HNGE Position
Active3-Fund ConvergenceRTW Investments initiated a new position in Hinge Health, Inc. (HNGE) in Q4 2025, holding $16.4M worth of shares across 353,500 shares.
HNGE is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
About Hinge Health, Inc.
Hinge Health, Inc. develops health care software for joint and muscle health. The company designs its platform to address a musculoskeletal care, acute injury, chronic pain, and post-surgical rehabilitation. It also provides various administrative and operations support services. The company was founded in 2012 and is headquartered in San Francisco, California.
Full company profile →Short Interest
7.6%
3.9 days to cover
Frequently Asked Questions
Does RTW Investments own HNGE?
Yes. As of Q4 2025, RTW Investments holds 353,500 shares of Hinge Health, Inc. (HNGE) valued at $16.4M. This data comes from their SEC 13F filing.
How many hedge funds own HNGE?
3 specialist biotech hedge funds currently hold HNGE, including RA Capital Management, Redmile Group. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did RTW Investments first buy HNGE?
RTW Investments's position in HNGE was first reported in Q4 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is RTW Investments's HNGE position increasing or decreasing?
RTW Investments initiated a new position in HNGE in the most recent quarter. This is their first reported holding.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
HNGECompany Page →
All fund holders, insider trades, catalysts, and cash runway
RTW InvestmentsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →